Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.

Slides:



Advertisements
Similar presentations
Regulation of Pharmaceutical Promotion: assessment, analysis & advocacy Lilia Ziganshina 20 May 2009 WHA.
Advertisements

19-20 September 2013, IBGE, Rio de Janeiro, Brazil
Delivering as One UN Albania October 2009 – Kigali.
Trade and Health National Assessment The World Health Organisations Diagnostic Tool on Trade and Health Presented by: Corinna Hawkes, Consultant
February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
National PSM Coordination Mechanism Dr Vincent Habiyambere WHO/HIV Department AIDS Medicines & Diagnostics Service (AMDS) Bangkok, July 2005.
The WHO Medicines Strategy Richard Laing Based on materials produced by Hans V. Hogerzeil, Essential Medicines and Pharmaceutical Policies November.
WHO STRATEGY FOR WORKING WITH COUNTRIES:REGIONAL AND COUNTRY PERSPECTIVE TECHNICAL BRIEFING SEMINAR,Geneva,19-23 September 2005 Dr. Jean-Marie TRAPSIDA.
WHO-Technical Briefing Seminar | 03 November 2010 Gilles Forte 1 |1 | WHO Technical Briefing Seminar Geneva November WHO Collaboration with.
Harmonized support to scaling up the national AIDS response Ini Huijts 7 th June 2006 ODI meeting, London.
TRTA – Component 1 Achievements & Results Presentation by Ms. Lilia Naas Mr. Arif Khan.
Strategies for Working with Countries – Regional and Sub-Regional Perspective and Experiences Essential Drugs and Medicines Policy WHO South-East Asia.
Towards a model M&E system for AIDS programs Kampala April
February Dakar, Senegal
USE OF REGIONAL NETWORKS FOR POLICY INFLUENCE: THE HIS KNOWLEDGE HUB EXPERIENCE Audrey Aumua and Maxine Whittaker Health Information Systems Knowledge.
Presentation by Cambodian Participants Phuket, Thailand February 2012 Health Impact Assessment Royal Government of Cambodia.
CSO’s on the Road to Busan: Key Messages and Proposals.
Session V: Programme Roles and Responsibilities
WHO GLOBAL ALCOHOL STRATEGY
Public health, innovation and intellectual property 1 |1 | WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Global Strategy and Plan.
System of Environmental-Economic Accounting SEEA Implementation Guide and Diagnostic Tool Alessandra Alfieri UNSD.
System of Environmental-Economic Accounting SEEA Implementation Guide and Diagnostic Tool and Suggested Structure for Assessment United Nations Statistics.
National Medicine Policy
Presentation on Managing for Development Results in Zambia By A. Musunga Director M&E MOFNP - Zambia.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Cross Border Animal Health Plan of Action – Kenya and Uganda Four Strategic areas 1. To improve prevention, management and control of cross border animal.
Working with Countries, Harmonisation and Regional Initiatives Technical Briefing Seminar MP Matsoso Director Department of Technical Cooperation for Essential.
Handicap-International Challenges of the Sustainability of physical rehabilitation sector Nepal, January 2013.
Michalis Adamantiadis Transport Policy Adviser, SSATP SSATP Capacity Development Strategy Annual Meeting, December 2012.
Initial thoughts on a Global Strategy for the Implementation of the SEEA Central Framework Ivo Havinga United Nations Statistics Division.
The IASC Humanitarian Cluster Approach Angelika Planitz UNDP BCPR Developing Surge Capacity for Early Recovery March 2006.
Toolkit for Mainstreaming HIV and AIDS in the Education Sector Guidelines for Development Cooperation Agencies.
Department of Technical Cooperation for Essential Drugs and Traditional Medicine (TCM) Roles and responsibilities in implementing the WHO Medicines Strategy.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
PACIFIC AID EFFECTIVENESS PRINCIPLES. Purpose of Presentation Provide an overview of Pacific Principles on Aid Effectiveness Provide an overview of Pacific.
Africa Health Workforce Platform & Observatory Presentation to the 1st conference of the Asia-Pacific Action Alliance on HRH (AAAH): October 2006.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Regional Strategy on Human Resources for Health (WHO Western Pacific Region) Presentation by Dr Ezekiel Nukuro Regional Adviser, Human Resources.
WHO support to countries in the area of medicines example of the African Region WHO/EDM Drug Action Programme.
Strategy for working with countries Work in progress Dr Gilles Forte Essential Medicines and Pharmaceutical Policies WHO Geneva Technical Briefing Seminar.
DEVELOPMENT COOPERATION FRAMEWORK Presentation by Ministry of Finance 10 December 2013.
1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
Indicators for monitoring and assessing pharmaceutical situation in countries.
WHO EURO In Country Coordination and Strengthening National Interagency Coordinating Committees.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
Observatories for the Health Workforce in Africa VIII REGIONAL MEETING OF THE OBSERVATORIES OF HUMAN RESOURCES FOR HEALTH IN THE AMERICAS LIMA, PERU
Indicators for monitoring and assessing pharmaceutical situation in countries Dr. Edelisa D. Carandang Drug Action Program (DAP) Essential Drugs and Medicines.
1.1.Recovery strategic planning capacities are strengthened. 1.2.Local capacity for ER planning and implementation strengthened in areas of expertise where.
EDM support to countries example of the African Region Gilles Forte WHO/EDM Drug Action Programme.
World Health Organization
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Waisea Vosa Climate Change Unit Division of Political and Treaties Ministry of Foreign Affairs and International Cooperation.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
WHO Estonia country office Marge Reinap Head of WHO Country Office in Estonia.
MOH 2 February Identify needs Prioritize needs Finalize list of endorsed needs Submit needs to MOPAD Consult with donor Negotiation (intra- and.
Social Protection Global Technical Team Retreat,
EMR Consultation, HRH Observatory, Tunis, September 2010
ADAPTATION TO CLIMATE CHANGE
WHO Medicines Work in Countries: The Kenya Example
Review of integrated PSM resources and tools and introduction to group work Upjeet Chandan ICCM FTT 17th February 2016.
Access framework HIV/AIDS, TB and Malaria
Advancing South-South Cooperation for Effective Implementation of
Essential Drugs and Medicines Policy (EDM) World Health Organization
Building Statistical Capacity UNSD perspective
Access to Essential Medicines
A year of progress on global and country coordination on PHC
Presentation transcript:

Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005

Mission Statement for working with countries ………using the WHO Medicines Strategy as a framework collaborate with countries to build a sustainable environment where quality, safe and effective essential medicines, including traditional medicines, are available, affordable and used appropriately ………….

WHO Medicines Strategy 2004 – 2007: 4 objectives, 7 components, 44 expected outcomes OBJECTIVES Policy Access Quality and safety Rational use COMPONENTS 1.Implementation and monitoring of medicines policies 2.Traditional and complementary medicine 3.Fair financing and affordability 4.Medicines supply systems 5.Norms and standards 6.Regulations and quality assurance systems 7.Rational use by health professionals and consumers

Strategic direction of TCM Department Ethical practices Collaboration/cooperation/ Building complementarities Values and Principles Key Areas Good governance/ accountability/ transparency Support countries to attain sustainable, uninterruptible, supply and appropriate use of affordable, quality, safe, efficacious medicines (including TM) for public health problems OBJECTIVE Demand/need driven Consistent message from WHO: HQ, RO's, CO's Promote appropriate use of essential medicines including traditional medicines Guide promoting local production and innovation (R&D) of new medicines for public health needs Assist in strengthening Pharmaceutical HR Provide technical guidance and support on TM National medicine policies: Support countries to develop, implement, evaluate & integrate NMP in health systems plan Assist countries in developing sustainable financing mechanisms Strengthen national capacity in drug and herbal medicines regulation to ensure quality, safety, efficacy Assist countries to protect public health in the negotiation and implementation of international, regional and bilateral trade agreement. Guide pricing policies and drug supply management Promote appropriate and safe use of EML and traditional medicines Guide policies on local production and innovation (R&D) of new medicines for public health needs Assist in strengthening Pharmaceutical Human Resources Provide technical guidance and support on TM Support countries to develop, implement, evaluate & integrate NMP in health systems plan Assist countries in developing medicines financing mechanisms Strengthen national capacity in drug and herbal medicines regulation to ensure quality, safety, efficacy Guide countries to protect public health negotiation and implementation of trade agreements. Guide pricing policies and drug supply management

HTP TCM PSM Other WHO Clusters Linkages with Regions & Country Offices Primary interaction Secondary interaction AFRO AMRO EMRO EURO SEARO WPRO Country Offices NPO

Headquarters (TCM): Support in planning and management and collaborations Provide and coordinate policy and technical support Support in HR development & training Assist in country assessments & monitoring Collaborative Activities Supporting WHO Medicine Strategy Guidance, support and collaborations Regional Offices: Oversee countries policies and support Planning and monitoring of country support Technical, policy and management support to countries Human resources development & training Partnerships and collaborations at regional level Country Offices: Assess needs and identify priorities for technical support Plan & implement WHO work Provide technical and policy support to countries Assist in coordination Partnerships & collaborations in countries Feedback and report Ministries of Health: Identify needs & priorities Plan, implement and monitor action Coordinate with other Ministries and national bilateral and multilateral agencies and CSO's. Strategic planning, implementation, monitoring

Enhanced expertise in countries assessing needs and priorities planning, implementation and monitoring of medicines policies coordination of stakeholders involved in pharmaceuticals feedback and reporting WHO Medicines advisers in about 30 countries to assist in:

Type B: Specific technical support Ad hoc or regular support usually focused on a subset of the following areas: policy; access: quality, safety & efficacy; and rational use Type C: Comprehensive programme support Time frame may cover one or more biennia Usually involves a full-time national programme officer Covers most or all of the following areas: policy; access, quality, safety & efficacy, and rational use Type A: Situation analysis & Monitoring Assessment of pharmaceutical situation, identify priority needs – recommendations for interventions Type IC: Inter-country Ad hoc or regular support involving two or more countries often in the same region Usually focused on a subset of the following areas: policy; access; quality, safety & efficacy; and rational use Activities Driven by Country Needs & Priorities Initiation of most activities are in response to requests by Member States. Other activities are based on WHA Resolutions, country specific needs.

Evidence based planning and interventions Data & evidence used, objectives and targets set, implementation plan developed, resources identified Regional/country plans & strategies implemented in coordination with partners: bilateral and multilateral agencies, NGOs, and other stakeholders Level I, Level II core indicators, household survey + other tools assess & monitor structures, processes, outcomes and specific pharmaceutical components

Indicators for monitoring and evaluation of pharmaceutical sector Level I Core indicators On structures & processes Level II Core indicators on outcomes/impact & household survey Level III Indicator tools for specific components of the pharmaceutical sector Pricing HIV/AIDS TRIPS Traditional medicine Etc, etc.

Monitoring and assessment to measure progress over time

Rationale for seeking evidence Raise awareness on realities and actual situation (qualitative observation with evidence) Provide numbers for advocacy to convince policy-makers, donors Identify problem areas and set priorities among possible areas for intervention Assess country medicines situation and trends over time Measures impact of interventions

HQ Regional Offices Country Offices Ministries of Health Ministries of Health Partners in Country Support WHO operational partners UNAIDS, bilateral and multilateral agencies, public interest NGOs in health, UNDP, UNFPA, UNCTAD UNICEF, EU WHO scientific partners WHO Collaborating Centres in pharmaceuticals, universities, research centres, international health professional associations WHO strategic partners World Bank and development banks, Donor Agencies, pharmaceutical industry, WTO, WIPO Links with other partners WHOCountries

WHO-HAI Africa Regional collaboration for action on essential medicines in Africa 1.Increased access to quality essential medicines through improved policies and advocacy – collaboration on affordability of medicines 2.Increased capacity and participation of NGOs and consumers in the development and implementation of medicines policy 3.Expanded participation in and strengthened coordination of the HAI Africa Network 4.Project countries: Uganda, Kenya and Ghana

Rationale for WHO-CSO collaboration in countries Synergy of expertise & know how Complementary mandates and approaches Enhance CSO participation in policy development & implementation Empower CSO and build capacity in the medicines field Increase impact on decision & policy makers Forge dialogue & links-changed NGO-MOH dynamics - helped close the NGO credibility gap Improve co-ordination and efficient use of resources